ABMD Stock Recent News

Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Abiomed (ABMD) possesses solid growth attributes, which could help it handily outperform the market.

Abiomed's Impella range of micro heart pumps enjoy rising demand in the marketplace. The company's OXY-1 System cardiopulmonary support device has strong growth prospect.

Abiomed's (ABMD) latest multi-center, multi-society study of Impella-supported patients is expected to significantly improve patient outcomes.

Abiomed's (ABMD) latest regulatory clearances for clinical research of Impella heart pumps in AMI cardiogenic shock patients are expected to significantly improve patient outcomes.

Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.

Abiomed's (ABMD) Impella-supported high-risk PCI leads to significant improvements in cardiovascular patient outcomes, per latest study.

The company's stock rose steadily throughout the month.

Abiomed, Inc. (NASDAQ:ABMD ) Q1 2023 Results Conference Call August 4, 2022 8:00 AM ET Company Participants Nicole Nath - Manager, Investor Relations Mike Minogue - President and Chief Executive Officer Todd Trapp - Vice President and Chief Financial Officer Conference Call Participants Brandon Vazquez - William Blair Marie Thibault - BTIG Pito Chickering - Deutsche Bank Chris Pasquale - Nephron Research Matt O'Brien - Piper Sandler Mike Polark - Wolfe Research Jayson Bedford - Raymond James Calvin Chu - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Abiomed FY '23 Q1 Earnings Call.

Abiomed came in with another set of robust earnings yesterday, with double-digit growth from top to bottom. Earnings remain steady, however, the company exhibits the profitability features investors are paying a premium for.